Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Working Capital Changes (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Other Working Capital Changes for 10 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 918.59% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.0 million, a 183.33% increase, with the full-year FY2025 number at $10.0 million, up 183.33% from a year prior.
  • Other Working Capital Changes was $2.7 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$9.9 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $17.5 million in Q1 2025 to a low of -$12.7 million in Q3 2024.
  • A 5-year average of -$1.0 million and a median of -$1.8 million in 2021 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: soared 1062.45% in 2022, then tumbled 1362.62% in 2024.
  • Ultragenyx Pharmaceutical's Other Working Capital Changes stood at -$7.0 million in 2021, then surged by 53.58% to -$3.2 million in 2022, then soared by 148.89% to $1.6 million in 2023, then crashed by 83.02% to $269000.0 in 2024, then surged by 918.59% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Working Capital Changes are $2.7 million (Q4 2025), -$9.9 million (Q3 2025), and -$313000.0 (Q2 2025).